- Aurinia Pharma press release ( NASDAQ: AUPH ): Q4 GAAP EPS of -$0.18 beats by $0.09 .
- Revenue of $28.4M (+21.4% Y/Y) misses by $0.42M .
- Cash, cash equivalents, and investments of $389.4 million as of December 31, 2022.
- For fiscal year 2023, the Company is reiterating its previous net product revenue guidance of $120 to $140 million from sales of LUPKYNIS. This range represents a double-digit percentage increase in net product revenue from sales of LUPKYNIS compared to fiscal year 2022.
For further details see:
Aurinia Pharma reports mixed Q4 earnings; reaffirms FY23 outlook